Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
9d
Live Science on MSNFDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Johnson & Johnson's Spravato ... Advertisement The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the Montgomery-Asberg Depression ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results